Immune checkpoint inhibitor therapy and outcomes from SARS-CoV-2 infection in patients with cancer: a joint analysis of OnCovid and ESMO-CoCARE registries

BACKGROUND: As management and prevention strategies against COVID-19 evolve, it is still uncertain whether prior exposure to immune checkpoint inhibitors (ICIs) affects COVID-19 severity in patients with cancer. METHODS: In a joint analysis of ICI recipients from OnCovid (NCT04393974) and European S...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortellini, Alessio, Dettorre, Gino M, Dafni, Urania, Aguilar-Company, Juan, Castelo-Branco, Luis, Lambertini, Matteo, Gennatas, Spyridon, Angelis, Vasileios, Sita-Lumsden, Ailsa, Rogado, Jacobo, Pedrazzoli, Paolo, Viñal, David, Prat, Aleix, Rossi, Maura, Berardi, Rossana, Alonso-Gordoa, Teresa, Grisanti, Salvatore, Dimopoulou, Georgia, Queirolo, Paola, Pradervand, Sylvain, Bertuzzi, Alexia, Bower, Mark, Arnold, Dirk, Salazar, Ramon, Tucci, Marco, Harrington, Kevin J, Mazzoni, Francesca, Mukherjee, Uma, Tsourti, Zoi, Michielin, Olivier, Pommeret, Fanny, Brunet, Joan, Vincenzi, Bruno, Tonini, Giuseppe, Patriarca, Andrea, Biello, Federica, Krengli, Marco, Tabernero, Josep, Pentheroudakis, George, Gennari, Alessandra, Peters, Solange, Romano, Emanuela, Pinato, David J
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Clinical/Translational Cancer Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716413/
https://www.ncbi.nlm.nih.gov/pubmed/36450384
http://dx.doi.org/10.1136/jitc-2022-005732

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9716413/
https://www.ncbi.nlm.nih.gov/pubmed/36450384
http://dx.doi.org/10.1136/jitc-2022-005732

Ejemplares similares